Últimas noticias sobre Ardelyx (NASDAQ:ARDX) Bolsa

Ardelyx

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Ardelyx Inc

ArdCoin

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $8.0, a high estimate of $11.00, and a low estimate of $5.50. Highlighting a 13.98% decrease, the current average has fallen from the previous average price target of $9.30. 
<img src="https://www.benzinga.com/files/images/story/2025/1738015232_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Ardelyx by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$5.50</td>
<td>$5.50</td>
</tr>
<tr>
<td>Chris Howerton</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Neutral</td>
<td>$5.50</td>
<td>-</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ardelyx. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ardelyx compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Ardelyx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ardelyx's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ARDX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ardelyx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Ardelyx's Background</h2>
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
<h3>Understanding the Numbers: Ardelyx's Finances</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Ardelyx's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 74.21%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -0.82%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ardelyx's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.53%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.23%, the company showcases effective utilization of assets.
Debt Management: Ardelyx's debt-to-equity ratio stands notably higher than the industry average, reaching 0.66. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ARDX

What Analysts Are Saying About Ardelyx Stock

Piper Sandler analyst Christopher Raymond maintains Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) with a Neutral and raises the price target from $7 to $8.

News

Price Target

Piper Sandler Maintains Neutral on Ardelyx, Raises Price Target to $8

HC Wainwright &amp; Co. analyst Ed Arce reiterates Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) with a Neutral and maintains $5.5 price target.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Ardelyx, Maintains $5.5 Price Target

WIIM

Ardelyx shares are trading higher after the company announced FY24 US sales of $319 million and projects IBSRELA revenue will surpass $1 billion.

Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million&nbsp;(unaudited)
Company reaffirms peak U.S. net IBSRELA sales revenue of greater than $1 Billion
Company announces peak U.S. net XPHOZAH sales revenue of $750 million
Company finishes 2024 with approximately $250 million in cash, cash equivalents and investments&nbsp;(unaudited)
WALTHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today provided an update on the company's progress in 2024 and initial expectations for 2025.

Biotech

Guidance

General

Ardelyx Announces 2024 U.S. Sales Of $319M, Projects IBSRELA To Surpass $1B, XPHOZAH At $750M; Ends Year With $250M In Cash And Investments

Across the recent three months, 4 analysts have shared their insights on Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $8.62, along with a high estimate of $11.00 and a low estimate of $5.50. Highlighting a 23.92% decrease, the current average has fallen from the previous average price target of $11.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1735848025_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Ardelyx among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Howerton</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Neutral</td>
<td>$5.50</td>
<td>-</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ardelyx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ardelyx compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Ardelyx's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ARDX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ardelyx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Ardelyx Better</h2>
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
<h3>Financial Milestones: Ardelyx's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Ardelyx showcased positive performance, achieving a revenue growth rate of 74.21% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -0.82%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.53%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Ardelyx's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.23% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 0.66, Ardelyx faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Ardelyx Stock

Jefferies analyst Chris Howerton maintains Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) with a Buy and lowers the price target from $11 to $8.

Jefferies Maintains Buy on Ardelyx, Lowers Price Target to $8

HC Wainwright &amp; Co. analyst Ed Arce downgrades Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) from Buy to Neutral and announces $5.5 price target.

Downgrades

HC Wainwright & Co. Downgrades Ardelyx to Neutral, Announces $5.5 Price Target

Legal

Judge Dismisses Ardelyx Lawsuit Against CMS Over XPHOZAH Inclusion In ESRD Payment System Starting Jan. 2025; CEO Mike Raab Voices Concern For Dialysis Patient Access And Urges Support For Kidney PATIENT Act As Company Explores Further Options Following Ruling

Citigroup analyst Yigal Nochomovitz maintains Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) with a Buy and lowers the price target from $12 to $10.

Citigroup Maintains Buy on Ardelyx, Lowers Price Target to $10

HC Wainwright &amp; Co. analyst Ed Arce reiterates Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) with a Buy and maintains $11 price target.

HC Wainwright & Co. Reiterates Buy on Ardelyx, Maintains $11 Price Target

Ardelyx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) reported its third-quarter results after Thursday's closing bell. Here's a look at the details <a href="https://www.benzinga.com/pressreleases/24/10/g41663791/ardelyx-reports-third-quarter-2024-financial-results-and-provides-business-update">from the report.&nbsp;&nbsp;</a>
The Details: Ardelyx reported quarterly sales of $98.24 million, which beat the analyst consensus estimate of $86.64 million.&nbsp;
The company reported IBSRELA generated $40.6 million in net product sales revenue and the company expects full-year 2024 IBSRELA net sales revenue to be between $145 million and $150 million.&nbsp;
XPHOZAH generates $51.5 million in net product sales revenue and Ardelyx ended the quarter with approximately $190 million in cash, cash equivalents and investments. 
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41631795/reddit-remains-a-favorite-for-wall-street-after-emphatic-beat-and-raise-in-q3">Reddit &#8216;Remains A Favorite&#8217; For Wall Street After &#8216;Emphatic Beat And Raise&#8217; In Q3</a>
&#8220;The continued strong performance of Ardelyx reported during the third quarter demonstrates our ability to execute and deliver on our goals, to focus on serving the patient and to build towards the future,&#8221; said Mike Raab, president and CEO of Ardelyx.
ARDX Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Ardelyx shares are up 3.07% after-hours at $6.05 at the time of publication Thursday.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41497160/starbucks-analysts-bullish-on-ceo-brian-niccol-after-tough-preannouncement-zeroing-">Starbucks Analysts Bullish On CEO Brian Niccol After Tough Preannouncement: &#8216;Zeroing In&#8217; On Right Issues</a></li>
</ul>
Photo: HeungSoon from Pixabay

Earnings

Health Care

Movers

Ardelyx Beats Q3 Sales Estimates, Shares Climb

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 28.5% to $0.55 during Thursday's after-market session. The market value of their outstanding shares is at $21.0 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 28.08% to $1.87. The company's market cap stands at $2.5 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) shares increased by 19.69% to $37.13. The market value of their outstanding shares is at $124.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock increased by 18.62% to $4.14. The market value of their outstanding shares is at $314.3 million. As per the news, the Q3 earnings report came out today. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock moved upwards by 7.7% to $54.49. The company's market cap stands at $6.9 billion. The company's, Q3 earnings came out today. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares rose 7.49% to $6.31. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock decreased by 10.6% to $1.1 during Thursday's after-market session. The company's market cap stands at $6.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock decreased by 5.74% to $1.47. The market value of their outstanding shares is at $10.1 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock decreased by 5.52% to $2.57. The company's market cap stands at $3.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares fell 5.49% to $7.75. The company's market cap stands at $18.6 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.23% to $0.83. The company's market cap stands at $28.8 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock decreased by 5.12% to $1.67. The market value of their outstanding shares is at $15.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATHA

BFRI

BRTX

CDXC

HALO

LUCY

OCEA

PALI

PDEX

TOVX

TRIB

12 Health Care Stocks Moving In Thursday's After-Market Session

Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) reported quarterly sales of $98.24 million which beat the analyst consensus estimate of $86.64 million by 13.39 percent. This is a 74.21 percent increase over sales of $56.39 million the same period last year.

Earnings Beats

Ardelyx Q3 Sales $98.24M Beat $86.64M Estimate

Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) is preparing to release its quarterly earnings on Thursday, 2024-10-31. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Ardelyx to report an earnings per share (EPS) of $-0.05.
Anticipation surrounds Ardelyx's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.04 in the last quarter, leading to a 10.0% increase in the share price on the following day.
Here's a look at Ardelyx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.11</td>
<td>-0.15</td>
<td>-0.09</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.07</td>
<td>-0.11</td>
<td>-0.12</td>
<td>0.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>28.000000000000004%</td>
<td>-2.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730311460_0.png" alt="eps graph" />
<h3>Analyst Opinions on Ardelyx</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Ardelyx.
With 3 analyst ratings, Ardelyx has a consensus rating of Buy. The average one-year price target is $11.33, indicating a potential 88.52% upside.
<h3>Comparing Ratings with Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Travere Therapeutics and Dynavax Technologies, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Buy trajectory for Travere Therapeutics, with an average 1-year price target of $22.17, indicating a potential 268.89% upside.</li>
<li>The consensus among analysts is an Buy trajectory for Dynavax Technologies, with an average 1-year price target of $24.33, indicating a potential 304.83% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for Travere Therapeutics and Dynavax Technologies, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ardelyx</td>
<td>Buy</td>
<td>227.86%</td>
<td>$63.79M</td>
<td>-11.05%</td>
</tr>
<tr>
<td>Travere Therapeutics</td>
<td>Buy</td>
<td>68.08%</td>
<td>$52.05M</td>
<td>-157.84%</td>
</tr>
<tr>
<td>Dynavax Technologies</td>
<td>Buy</td>
<td>22.48%</td>
<td>$61.81M</td>
<td>1.81%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Ardelyx ranks highest in Revenue Growth among its peers. It has the lowest Gross Profit margin. Ardelyx has the lowest Return on Equity compared to its peers.
<h3>About Ardelyx</h3>
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
<h3>Unraveling the Financial Story of Ardelyx</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Ardelyx's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 227.86%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -22.47%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ardelyx's ROE excels beyond industry benchmarks, reaching -11.05%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Ardelyx's ROA excels beyond industry benchmarks, reaching -4.8%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.71, Ardelyx adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/ARDX/earnings">To track all earnings releases for Ardelyx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Ardelyx's Earnings Outlook

Ardelyx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of XPHOZAH&#xAE; (tenapanor) was presented in a series of poster presentations at the American Society of Nephrology's (ASN) Kidney Week, currently taking place in San Diego. Ardelyx is also hosting an Exhibitor Spotlight discussing hyperphosphatemia management.
XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different mechanism of action that blocks phosphate absorption at the primary pathway and is administered as a single tablet taken twice daily.

Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH At The American Society Of Nephrology's Kidney Week

Ardelyx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting XPHOZAH&#xAE; (tenapanor) will be presented at the American Society of Nephrology's (ASN) Kidney Week, to be held October 24-27, 2024, in San Diego. &nbsp;
XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different mechanism of action that blocks phosphate absorption at the primary pathway and is administered as a single tablet taken twice daily.

Ardelyx To Present Additional Data Supporting First-In-Class XPHOZAH For Adults With Chronic Kidney Disease On Dialysis At The American Society Of Nephrology's Kidney Week

Ardelyx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the recent publication of a review article, titled "Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome With Constipation in the United States" in Clinical and Experimental Gastroenterology, an international, peer reviewed, open access journal focusing on all aspects of gastroenterology research, as well as clinical results in human, animal and in vitro studies that shed light on disease processes and potential new therapies. &nbsp;
The article provides an overview of treatment options and disease management for irritable bowel syndrome with constipation (IBS-C) from a U.S. perspective and discusses the importance of the relationship between patient and health care provider in diagnosis and treatment. It recommends a positive diagnostic strategy for IBS-C, based on clinical history, physical examination, and minimal laboratory tests.

Ardelyx Announces Publication Of A Review Article Exploring 'The Patient Burden And Therapeutic Landscape Of IBS-C In The U.S.' In Clinical And Experimental Gastroenterology

HC Wainwright &amp; Co. analyst Ed Arce maintains Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) with a Buy and raises the price target from $10 to $11.

HC Wainwright & Co. Maintains Buy on Ardelyx, Raises Price Target to $11

Citigroup analyst Yigal Nochomovitz maintains Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) with a Buy and raises the price target from $10 to $12.

Citigroup Maintains Buy on Ardelyx, Raises Price Target to $12

IBSRELA records approximately $158 million in net product sales revenue in 2024: U.S. net product sales revenue for IBSRELA during the fourth quart...

Ardelyx reports preliminary Q4 IBSRELA revenue $54M

Ardelyx provides update on commercial progress; shares up 8%

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Ardelyx (ARDX – Research Report) today and set a price target of $5.50. Ed Arce has giv...

Ardelyx's Mixed Financial Outlook: Hold Rating Amid IBSRELA Growth and XPHOZAH Challenges

In a regulatory filing, Ardelyx (ARDX) disclosed that its director David Mott bought 199K shares of common stock on January 21st in a total transac...

Ardelyx director buys $992.7K in common stock

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGS –&nbsp; Knight-Swift Transportation&nbsp;(K...

Closing Bell Movers: Electronic Arts down over 10% on guidance cut

Ardelyx spikes as chairman buys nearly $1M worth of stock

Piper Sandler analyst Christopher Raymond assigned a Hold rating to Ardelyx (ARDX – Research Report) today and set a price target of $8.00. The com...

Piper Sandler Releases a Hold Rating on Ardelyx (ARDX)

Piper Sandler raised the firm's price target on Ardelyx (ARDX) to $8 from $7 and keeps a Neutral rating on the shares ahead of earnings. With biote...

Ardelyx price target raised to $8 from $7 at Piper Sandler

TD Cowen analyst Joseph Thome maintained a Buy rating on Ardelyx (ARDX – Research Report) today and set a price target of $12.00. The company's sha...

Ardelyx (ARDX) Receives a Buy from TD Cowen

APTV

ARWR

ASTS

CACI

CGEN

CLRB

EVTL

GWRE

IBIO

MRNA

NVEC

PHIO

PLXS

SAGE

SLRX

STLD

XCUR

Press Releases

ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Ardelyx

Noticias

Últimas noticias sobre Ardelyx (NASDAQ:ARDX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL